Herbal products are gaining in popularity in large part because consumers believe that they are "natural", safer, more effective, have fewer side effects, and can be obtained at a lower cost than conventional therapies (Elvin-Lewis, 2001) .
Consequently, herbal products are widely used by women to alleviate discomfort associated with menstruation, pregnancy/labour, premenstrual syndrome and menopause (Beal, 1998) . Herbals commonly used for these reproductive complaints include black cohosh (Actaea racemosa), chaste tree berry (Vitex agnus-castus), crampbark (Viburnum opulus), and false unicorn (Chamaelirium luteum) (Beal, 1998; Roemheld-Hamm, 2005; Ross, 2007) Natural products are often thought to be safe, yet some herbal preparations contain constituents that inhibit cytochromes P450 (CYP450) (Fugh-Berman and Ernst, 2001) . Since many women take both herbals and prescription medications simultaneously (Refuerzo et al, 2005) there is a potential for interactions to occur (Fugh-Berman and Ernst, 2001) . However, there is no predictive pharmacokinetic database that would assist users and prescribers in avoiding potential interactions. This is in stark contrast to the development of pharmaceuticals where predictive pharmacokinetics plays a major role in the progression from lead compound to candidate drug (Cohen et al, 2003) . Other important differences between pharmaceuticals and herbals are: i) that the former normally have only one active chemical entity whereas herbals -including those in this study -often have multiple components (Gödecke et al, 2009) , and those components that are pharmacologically active are not necessarily the ones that are pharmacokinetically active; ii) that the relative amounts of various constituents of herbals can vary markedly from preparation to preparation (Gödtel-Armbrust et al, 2007) .
The specific aim of this study was to establish predictive CYP450 interaction kinetics for specific commercial preparations of black cohosh root, chaste tree berry, crampbark and false unicorn that are readily available to consumers in Hamilton, Ontario. To achieve this we examined the ability of these herbal preparations to inhibit the biotransformation of fluorogenic substrates by the major human drug metabolizing enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 which account for 5%, 10%, 15%, 20-30%, and 40-45% of total drug biotransformations, respectively (Ingelman-Sundberg, 2004) . We also investigated their actions on human CYP1A1, which is implicated in both the activation and detoxification of a number of carcinogens (Androutsopoulos et al, 2009 ). Since there is some controversy about the appropriateness of various methods for screening CYP activity (Strandell et al, 2004; Unger and Frank, 2004) , a more general aim was to assess the usefulness of the rapid screening of herbals against human cytochromes P450 using fluorogenic substrates as an efficient way to acquire information on potential interactions. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Materials and Methods

Materials
All assay reagents were purchased from Sigma-Aldrich (Oakville, ON, Canada).
Recombinant human cytochrome P450 enzymes (CYP450) were obtained from BD Biosciences (Mississauga, ON, Canada). All substrates and fluorescent product standards were obtained from BD Gentest (Woburn, MA, USA) except for the Vivid ® Red CYP2C9 (Vivid Red) substrate from Invitrogen (Burlington, ON, Canada). Solvents were of analytic or high-performance liquid chromatography (HPLC) grade.
Commercial liquid (ethanolic) extracts of black cohosh and chaste tree berry (Gaia Herbs, Brevard, NC, USA) and crampbark and false unicorn (St Francis Farms, Cobermere, ON, Canada) were obtained from local retailers.
Preparation of Herbal Products
Commercial extracts of the herbal preparations were diluted in assay buffer so that the final concentration of ethanol in the assays was 1%.
Cytochrome P450 Assay
The velocity of biotransformation of 7-ethoxyresorufin (ERES) by CYP1A1 (0.2 pmol/well), 3-cyano-7-ethoxycoumarin (CEC) by CYP1A2 & CYP2C19 (0.5 and 2 pmol/well, respectively), Vivid Red by CYP2C9 (6.8 pmol/well), 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) by CYP2D6 (5 pmol/well) and 7-benzyloxyquinoline (BQ) by CYP3A4 (1 pmol/well) were determined by fluorometric assays using the general principles as described (Crespi et al, 1997; Marks et al, 2004) . Reactions were carried out at 37°C in black 96-well 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Softmax Pro) . In all cases the fluorescence intensity was calibrated with authentic product and the duration of the incubation and the CYP450 concentration were in the linear range of metabolite formation. In experiments to examine the ability of standard compounds and herbal preparations to inhibit CYP450 activity, wells contained fixed concentrations of substrate (Table 1) , the putative inhibitors, and the appropriate vehicle which was also present in control wells.
Detection of autofluorescence and fluorescence quenching
Increasing concentrations of herbal preparations were diluted in phosphate buffer or 
Data Analysis
Kinetic parameters for each of the enzymes were determined by fitting plots of the reaction velocity versus substrate concentration to different kinetic models by nonlinear least-squares regression. The simplest model was the Michaelis-Menten model given by the equation:
where V is the reaction velocity at substrate concentration [S], V max is the maximum velocity of the reaction and K m is the Michaelis-Menten constant.
In some cases, the Hill model which can be described by equation 2 was used:
where n is the Hill coefficient.
In cases where a downturn in the enzyme kinetics at high substrate concentrations suggested the possibility of substrate inhibition, this was followed by fitting the data to equation (3), adopted from Kenworthy et al (2001) based on the principles defined by Segel (1975) , which assumes that the substrate binds with equal affinity to two sites on the enzyme and allows for interaction between the two sites:
where β reflects the degree to which the two occupied sites interact to alter the effective catalytic rate constant (when β = 1 there is no change in the rate of product formation). The applicability of increasingly complex models over simple models was assessed using the F-test (Motulsky and Ransnas, 1987) at P < 0.05.
The effects of putative inhibitors were expressed as a percentage of control according to the following equation:
where E represents the percentage change with respect to control, V c is the reaction velocity in the presence of putative inhibitor, B is the reaction velocity in the absence of enzyme and C is the reaction velocity in the absence of putative inhibitor.
Inhibitory effects were subsequently assessed using a nonlinear least-squares fitting to the simple competitive binding equation:
where [X] is the concentration of the putative inhibitor and pIC 50 is the negative log of the concentration that inhibits enzyme activity by 50%. For herbals the pIC 50 is in units of g/mL. For standard compounds, the molar pIC 50 values were converted to pK i (molar inhibition constant) values according to equation (6) adapted from Cheng & Prusoff (1973) on the assumption that the nature of inhibition is independent of the kinetic model:
When data were tabulated, the pIC 50 and pK i values were converted to IC 50 (µg/mL) and K i (µM), respectively, for ease of interpretation. IC 50 values were also compared to the concentrations (µg/mL) that would be attained from single recommended doses 1C ). Kinetic plots of reaction velocity versus substrate concentration for CYP1A1, CYP2C9 and CYP2D6 were best fit by simple Michaelis-Menten kinetics (eq 1), whereas CYP1A2 ( Fig 1B) and CYP2C19 followed complex kinetics described by the Hill model (eq 2). The kinetics for CYP3A4 ( Fig 1D) followed the substrate inhibition model described by equation (3). Table 2 summarizes the kinetic parameters of the cytochrome P450 enzymes and the effects of standard inhibitors are given in Table 1 .
All herbal preparations produced some degree of fluorescence quenching or autofluoroescence at some wavelengths when used at high concentrations. This often reduced the maximum concentrations that could be used in the assays. By limiting the maximum concentrations used to those producing no more than a 10% change in the fluorescence intensity of the amount of product generated under standard conditions, we were still able to estimate the inhibitory potential of the herbal preparations. The maximum concentrations for each herbal used in each assay are listed in Table 3 .
Concentration-dependent inhibition of CYP450 activity by chaste tree berry extract is shown in Fig. 2 . The effects of all the herbal preparations on the human CYP450 enzymes are summarized in Table 4 . CYP1A2, CYP2C19, CYP2D6 and CYP3A4 were each inhibited by at least one of the herbal preparations, whereas CYP1A1 and CYP2C9 were unaffected. For preparations that showed activity, the IC 50 values ranged from as low as 0.22 µg/mL to as high as 9.7 µg/mL, in all these cases, concentrations higher than those required to produce 50% inhibition of CYP activity would be attained from a single dose of herbal even if the active compound (s) were distributed in the total body water volume, assuming 100% bioavailability. 
Discussion
We chose to use fluorimetric, microplate-based assays because they are homogeneous, sensitive, easy to perform, and have a high throughput that would be ideal for initial of screening of large libraries of commercial herbal products for potential interactions with cytochromes P450 (Crespi et al, 1997; Ghosal et al, 2003; Strandell et al, 2004) . The kinetic parameters that we determined (Table 2 ) are in good agreement with previously published data (Ghosal et al, 2003; Marks et al, 2004; Stresser et al, 2000) , some minor differences are likely due to different experimental conditions. We detected atypical kinetics for CYP1A2, CYP2C19, and CYP3A4
( Table 2) . Complex allosteric interactions are fairly common among cytochromes P450 (Houston and Kenworthy, 2000) , but are not observed consistently (Ghosal et al, 2003; Stresser et al, 2000) . We validated the assays by showing that standard inhibitors of each respective CYP isoform acted with an appropriate potency (Table 1) .
Again, there is good agreement between our data and those of others using quite diverse methods (Ghosal et al, 2003; Marks et al, 2004; Shimada and Guengerich, 2006; Unger and Frank, 2004) .
We began this study with the assumption that the benefits of fluorimetric, microplate-based assays would outweigh those of alternate methods such as liquid chromatography/mass spectrometry (Unger and Frank, 2004) which require complex instrumentation, dedicated personnel and additional sample extraction procedures.
One notable disadvantage of fluorogenic substrates is that results obtained do not always agree with those from conventional substrates. For instance there was a large discrepancy between the observed interaction of compounds with CYP3A4 when the fluorogenic probe Vivid Red was used as substrate as opposed to when the (Cohen et al, 2003) .
This phenomenon puts some constraints upon the interpretation of the data (Cohen et al, 2003) . However, there is also lack of agreement among conventional substrates, and a general principle that the choice of the probe substrate has a significant impact on the drug interaction profile of a given agent has emerged (Foti and Wahlstrom, 2008) . Clearly, with a task as large as the initial screening of herbals for their interactions with CYP450s, the use of a library of substrates for each isoform is impractical. Cohen et al (2003) support the continued use of fluorogenic substrates for the initial identification of the potential of new chemical entities to interact with CYP450s, provided that follow-up studies are carried out on drug candidates with conventional probes. Similar principles could be adopted for herbals with follow-up studies being performed on the more potent interactions.
We compared the inhibitory potencies of the herbals to the concentrations that would be attained from single recommended doses of each preparation at three different volumes of distribution which corresponded to plasma volume, the volume of extracellular water and total body water by assuming 100% bioavailability of the active principle (Table 4 ). For black cohosh against CYPs 2D6 and 1A2
concentrations from a single dose distributed in total body water were approximately 7 and 35 times higher than the in vitro IC 50 values, respectively. Thus, the potencies of black cohosh against these two isoforms seem sufficiently high to merit concern, yet in vivo data argue against this (Gurley et al, 2005; Gurley et al, 2008) . Results of this study did identify some potent inhibition of CYP450 activity ( 2005) , we found no effect of the commercial extract at the low concentrations we were able to test, and this is in agreement with in vivo data suggesting no clinically relevant interactions between black cohosh and CYP3A4 (Gurley et al, 2006) . Similar in vivo experiments discount the clinical significance of the inhibition of CYP2D6 by black cohosh (Gurley et al, 2008) which was significant in our assays but was the lowest activity that we measured (Table 4 ). In vivo studies also do not support any clinically significant interactions between black cohosh and CYP1A2 (Gurley et al, 2005) whereas we found the inhibition to be quite potent (Table 4 ). However, the most potent inhibitory effect of black cohosh was against CYP2C19 (Table 4) for which no in vivo data are available at present. While the discrepancies might be explained by differences in the herbal preparations used in the in vivo studies compared to ours, a more likely explanation is that the active inhibitory components are poorly bioavailable. The majority of evidence (summarised by Unger and Frank, 2004), suggests that polyphenolic constituents of herbals have a very low oral bioavailability, while other components are reported to have high bioavailability (see Strandell et al, 2004) .
Adverse events following the consumption of chaste tree berry are usually mild and reversible (Daniele et al, 2005; Dugoua et al, 2008) with no drug interactions identified by systematic reviews of the literature. However, neither in vitro nor in vivo pharmacokinetic studies with this herb have been reported to date. We found that chaste tree berry extract inhibited CYPs 1A2, 2C19, 2D6 and 3A4 at concentrations in the µg/mL range or lower. In comparison to predicted concentrations in vivo, effects on CYPs 2C19 and 3A4 were particularly potent (Table   4 ).
There are no prior studies on the pharmacokinetics of crampbark and false unicorn. Both were potent inhibitors with IC 50 s close to 1 µg/mL; crampbark of CYPs 1A2 and 2C19 and false unicorn of CYPs 2D6 and 3A4 (Table 4 ).
Because of some necessary assumptions about pharmacokinetic properties of
test substances and the nature of the assays themselves, CYP450 inhibition kinetics cannot be relied upon to accurately predict herb/drug interactions. This principle is aptly demonstrated in the case of black cohosh discussed above where its high in vitro potency against CYPs 2D6 and 1A2 does not lead to significant clinical effects.
However, the cost of performing in vivo experiments on all herbal preparations -let alone the enormity of the task -would be prohibitive. Therefore a more practical approach is to accept the lower predictive power of CYP450 inhibition kinetics alone, prioritise preparations according to their inhibitory potency and their frequency of use and then proceed directly to in vivo experiments. Although the methods we have described have some limitations brought about by inherent fluorescence properties of some herbals, they provide a relatively fast and efficient means of obtaining the necessary preliminary data on large numbers of preparations simultaneously.
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